

Title (en)
NEUROBLASTOMA TREATMENT WITH TAUROLIDINE HYDROLYSIS PRODUCTS

Title (de)
NEUROBLASTOMBEHANDLUNG MIT TAUROLIDIN-HYDROLYSEPRODUKTEN

Title (fr)
TRAITEMENT DU NEUROBLASTOME AVEC DES PRODUITS D'HYDROLYSE DE TAUROLIDINE

Publication
EP 3843746 A1 20210707 (EN)

Application
EP 19856239 A 20190828

Priority
• US 201862723618 P 20180828
• US 2019048592 W 20190828

Abstract (en)
[origin: WO2020047113A1] Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically- resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. The efficacy in rodent model is superior to the efficacy in cell culture. This invention relates to the use of taurolidine hydrolysis products (tarultam and/or taurinamide and/or methylene glycol and/or selected combinations thereof) for the treatment of neuroblastoma in juvenile mammals.

IPC 8 full level
A61K 31/54 (2006.01); **A61K 31/541** (2006.01); **A61K 31/549** (2006.01)

CPC (source: EP KR)
A61K 9/0019 (2013.01 - EP KR); **A61K 9/5146** (2013.01 - KR); **A61K 9/5153** (2013.01 - KR); **A61K 31/18** (2013.01 - EP KR); **A61K 31/549** (2013.01 - EP KR); **A61K 45/06** (2013.01 - EP KR); **A61K 47/10** (2013.01 - EP KR); **A61K 47/60** (2017.08 - KR); **A61P 35/00** (2018.01 - KR); **A61K 2300/00** (2013.01 - KR)

C-Set (source: EP)
1. **A61K 31/549 + A61K 2300/00**
2. **A61K 31/18 + A61K 2300/00**

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2020047113 A1 20200305; AU 2019330954 A1 20210422; CA 3111057 A1 20200205; CN 113347976 A 20210903; EP 3843746 A1 20210707; EP 3843746 A4 20221019; JP 2021535163 A 20211216; KR 20210050544 A 20210507

DOCDB simple family (application)
US 2019048592 W 20190828; AU 2019330954 A 20190828; CA 3111057 A 20190828; CN 201980071416 A 20190828; EP 19856239 A 20190828; JP 2021511544 A 20190828; KR 20217008971 A 20190828